The Oncology Institute reports developments in value-based community oncology care, combining oncology and hematology services with specialty pharmacy, patient services, clinical trials, transfusions, and related care models. Its updates center on operating results, specialty pharmacy volume, gross profit and cash flow trends, and the performance of capitated and Medicare Advantage payor relationships.
Company news also covers participation in CMS oncology payment models, contract expansion across community oncology markets, clinical pathway and provider engagement initiatives, investor conference appearances, and governance or compliance leadership changes. The business operates through Specialty Pharmacy, Patient Services, and Clinical Trials and Other segments.
The Oncology Institute (NASDAQ: TOI) has announced a significant partnership with SilverSummit Healthplan, becoming the exclusive oncology provider for over 80,000 Medicaid patients in Nevada, effective July 1. This expansion marks an important step in TOI's mission to provide value-based cancer care to underserved communities.
The partnership will operate through three Nevada locations in Las Vegas, Henderson, and Spring Valley, offering comprehensive cancer care services to SilverSummit Healthplan members. This collaboration aligns with TOI's track record of serving Medicaid patients and SilverSummit's commitment to providing high-quality healthcare access to its members.
The Oncology Institute (NASDAQ: TOI) has appointed Dr. Jeffrey Langsam as its new enterprise Chief Clinical Officer (CCO), effective May 13th, 2025. In this role, Dr. Langsam will oversee therapeutics, including pathway and procurement decisions, utilization management, and MSO practice clinical engagement.
Dr. Langsam joins TOI from Cigna Healthcare, where he served as National Director of Oncology and Senior Medical Director in the Specialty Pharmacy Division. His previous experience includes roles as Regional Medical Director at Aetna and clinical faculty at the University of Connecticut, where he practiced as an oncologist.
The appointment comes as TOI experiences acceleration in new value-based partnerships and growth in its MSO model across the country.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, announced its participation in the upcoming B. Riley's 25th Annual Institutional Investor Conference. The event will take place on May 21st, 2025, in Marina Del Rey, CA. The company will be represented by CEO Dr. Daniel Virnich and CFO Rob Carter.
The Oncology Institute (NASDAQ: TOI) has been selected to present significant findings at the upcoming ASCO Annual Meeting regarding their High-Value Cancer Care (HVCC) model. The study demonstrates remarkable improvements in patient care and cost efficiency:
Key outcomes include:
- 53% reduction in Emergency Department use
- 68% decrease in hospitalizations
- 75% lower odds of acute care facility death
- $12,000 cost savings per enrolled patient
According to TOI's Chief Medical Officer, Dr. Yale Podnos, these results validate their coordinated care approach in delivering superior clinical outcomes while significantly reducing costs for patients and payor partners.
The Oncology Institute (TOI), a leading value-based oncology group in the United States, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on Wednesday, May 14, 2025, followed by a conference call at 5:00 p.m. Eastern Time.
Investors can access the conference call via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or through a simultaneous webcast on TOI's Investor Relations website. A replay will be available for one week until May 21, 2025, using passcode 13752832.
The Oncology Institute (NASDAQ: TOI) has announced an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, building upon their existing collaboration in Florida. The expanded partnership aims to enhance access to cancer clinical trials across TOI's markets.
The collaboration focuses on integrating clinical research into community oncology settings, with key benefits including:
- Increased patient access to leading-edge therapies
- Streamlined study activation and enrollment processes
- Enhanced trial performance through unified oversight
- Improved infrastructure for regulatory and operational support
TOI CEO Daniel Virnich emphasized that this expansion will help scale their research infrastructure while maintaining focus on patient care. Chief Medical Officer Yale Podnos highlighted the initiative's goal of making clinical research a routine part of patient care across all markets, with a shared commitment to advancing health equity in oncology research.
The Oncology Institute (NASDAQ: TOI) has launched the Florida Oncology Network, a fully delegated cancer care network, marking a significant expansion in Florida's healthcare landscape. The network combines TOI Clinics with value-focused medical and radiation oncologists across the state to deliver coordinated, accessible, and affordable cancer care.
TOI has partnered with Provider Network Solutions (PNS) to manage claims administration and network operations. The collaboration leverages TOI's clinical model with PNS's expertise in delegated provider networks in Florida. The network is immediately operational, with plans for expansion throughout 2025.
Additionally, TOI has secured four new value-based contracts in Q1 2025, adding 80,000 lives, including 42,000 Medicare Advantage lives under the new fully delegated model in Florida.
The Oncology Institute (NASDAQ: TOI) reported its Q4 and full-year 2024 financial results. Q4 highlights include consolidated revenue of $100 million, up 16.9% year-over-year, with a net loss of $13.2 million compared to $18.8 million in Q4 2023. The company achieved positive cash flow from operations of $4.2 million in Q4.
Key operational developments include a 12% reduction in SG&A expenses, new drug supplier agreements with improved discounts, and the launch of six new contracts covering over 250,000 lives. Value-based patient services increased by 15% from Q3 2024.
For full-year 2024, TOI reported consolidated revenue of $393 million, a 21.3% increase, though patient services revenue decreased 4% due to a lost contract. The company expects Q1 2025 Adjusted EBITDA of $(5) to $(6) million, citing seasonal factors such as drug price increases and lower encounter volumes.